Monteris Study Links 91% NeuroBlate Ablation to Longer Brain Tumor Survival

3 articles · Updated · Mass Device · Aug 20

787 patients in Monteris Medical’s LAANTERN study showed significantly longer progression-free and overall survival when NeuroBlate ablated at least 91% of tumor volume; earlier treatment of smaller metastatic lesions also improved survival.
The prospective multicenter post-market study is tracking more than 1,000 enrolled patients for up to five years to generate real-world evidence on how the MR-guided laser ablation system is used in neuro-oncology.
63% of patients avoided intensive care after the minimally invasive procedure, while hospital stays were short and postoperative recovery was quicker, according to the study.
30% to 40% of patients stopped anticonvulsants, 80% stopped steroids, and quality of life remained stable for up to three years, supporting NeuroBlate’s role as an earlier treatment option rather than a last resort.